{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.7","upperLimit":"95.9","value":"90.5"},{"groupId":"OG001","lowerLimit":"77.3","upperLimit":"92.4","value":"86.7"},{"groupId":"OG002","lowerLimit":"51.1","upperLimit":"79.9","value":"67.8"},{"groupId":"OG003","lowerLimit":"82.7","upperLimit":"94.4","value":"90.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"119"}],"units":"Participants"}],"description":"Probability of survival was defined as the probability of being alive at Month 6.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).","id":"OG000","title":"RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).","id":"OG001","title":"RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).","id":"OG002","title":"RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).","id":"OG003","title":"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"}],"paramType":"NUMBER","populationDescription":"SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, \"Overall number of participants analyzed\" signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.","reportingStatus":"POSTED","timeFrame":"Month 6","title":"Probability of Participant Survival at Month 6","type":"PRIMARY","unitOfMeasure":"Probability of participants survival"}